ORTEXORTEX News
Tracking PJT? Get live short interest, options flow, and signals on ORTEX.Sign up free →
PJ
Earnings PreviewPJT

PJT Partners Heads Into Q3 Print With Analysts Cutting Targets

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 2 min readdata as of 24 Oct 2026, 04:02

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

PJT Partners reports Q3 results on October 27 with a notable cooling in analyst conviction since the last print, even as the stock edges higher on the week.

The clearest pre-earnings signal is the recent analyst tone shift. Three of the most-watched firms trimmed targets in the three weeks before the print. Goldman Sachs cut from $203 to $182 while holding its Buy rating. Keefe, Bruyette & Woods went further, downgrading to Market Perform and slashing its target from $195 to $159. UBS held Neutral and lowered from $176 to $165. The consensus mean price target now sits at $161, against a current price of $140.94, leaving roughly 14% implied upside, but the direction of revisions matters as much as the level, and the trend here is clearly downward. The stock itself has fallen 6.2% over the past month, sitting well below where it was after the July print, when the shares briefly touched the mid-$170s.

Bulls point to PJT's record mandate count and the strength of the Park Hill division, particularly in Private Equity and Private Capital Solutions, as evidence that the firm is capturing a larger share of a recovering advisory market. Elevated restructuring activity is seen as a revenue cushion if the M&A cycle remains uneven. Bears, however, question the pipeline visibility beyond restructuring, and worry that with the PE multiple near 17x and the price-to-book above 13x, the valuation leaves little room for a miss. The EPS momentum factor score has slipped to the 11th percentile over 30 days, a sign that near-term estimate revisions have been running against the stock heading into the quarter.

Insider activity over the 90 days through mid-September adds another cautious note. Net open-market sales across directors totalled roughly $2.1m, with no offsetting discretionary purchases. The June transactions in the data were compensation-related option exercises rather than conviction buys, so the picture from the C-suite and board is one-directional. That said, the borrow market tells a calmer story: availability is wide at roughly 733%, meaning there are more than seven shares available to lend for every one already borrowed, and cost to borrow is just 0.43%. Short interest at 7.2% of the free float is not negligible, but it has been drifting lower all month after peaking near 7.9% in late September. Squeeze dynamics are not part of the current setup.

Options positioning is broadly neutral. The put/call ratio at 0.70 is fractionally below its 20-day average of 0.71, and the z-score of -0.45 shows no meaningful tilt toward either protection or speculation. Retail attention is another data point worth flagging: Wikipedia page-view momentum is running more than 2.7 standard deviations above its own 90-day history, an unusual spike in public interest for a mid-cap advisory boutique in the days before a print.

The October 27 report will test whether PJT's restructuring franchise and Park Hill momentum are enough to justify the premium valuation after a month of target cuts, or whether the firm needs to show meaningful M&A pipeline recovery to reassert the bull case.

Stocks in this article

See the live data behind this article on ORTEX.

Open PJT on ORTEX →

How this article was generated

Generated
24 Oct 2026, 04:28
Data as of
24 Oct 2026, 04:02
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.